>>> Wirecard (WEI GY) - Research Report from Small boutique

see attached

* Wirecard has avoided publicly responding to the issues we raised. Instead, Wirecard has disseminated false and misleading information to ‘Sell Side’ analysts and Investors. 
* Wirecard has been caught in one of its lies. Having been confronted with evidence from UK Companies House, Wirecard now admits it did incorporate Wire Card UK Ltd.
* This is a significant and devastating admission that directly connects Wirecard to online gambling companies and companies laundering money into the United States. 
* The United States Secret Service was unaware of Wirecard's incriminating connections to these companies at the time of its investigation. The important company filings that 60 show these connections were filed after the U.S. Secret Service’s initial investigation. 
* This is significant and new evidence demonstrating Wirecard's central involvement in transmitting unlawful monies into the United States. Evidence that the United States Secret Service is now becoming aware of. 
* Zatarra will reveal new evidence demonstrating the fraudulent nature of Wirecard’s operations in due course.

>>> ECB has purchased €608B worth of bonds in public sector purchase program (PS

ECB has purchased €608B worth of bonds in public sector purchase program (PSPP, QE) as of w/e Mar 4th v €594.8B prior week 
- Total ABS purchases (ABSPP) to date now €18.9B vs. €18.64B prior 
- ECB has now purchased total €159.9B vs. €158.0B prior under its covered bond purchase program 3 (CBPP3)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: VNR -17.2%, ROKA -7.4%, EC -2.5%, GEF -1.7%, SSL -0.7%, SSL -0.7%


Select EU bellwethers showing weakness: DB -2.8%, RBS -2.4%, IHG -2.3%, HSBC -2%, SNY -1.3%, SAN -1.1%, AZN-1.1%, GSK -1%, BCS -0.9%, SHPG -0.8%, NVS -0.7%


Other news: CLDX -50.5% (to discontinue its Phase 3 ACT IV study of RINTEGA in patients with newly diagnosed EGFRvIII-positive glioblastomane discontinued following DSMB preplanned interim analysis), SDRL -13.9% (pulling back pre-mkt after last week's 200%+ gains), PLUG -2.8% (cont weakness), PLD -1.2% (prices new investment units at JPY231,574 per unit)

Analyst comments: ROKA -7.4% (downgraded to Mkt Perform from Outperform at Leerink Partners), SSYS -4.1% (downgraded to Underweight from Neutral at JP Morgan), MU -3.9% (downgraded to Reduce from Neutral at Nomura)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: NVIV +24.3%, ARP +14.1%, PIR +6.6%, TACO +6.6%, VNCE +2.2%

M&A news: DD +3.1% (report that BASF (BASFY) might make a takeover bid for the company), RAI +2.3% (The Telegraph discusses speculation that British American Tobacco (BTI) could move to acquire the remaining stake in RAI it doesn't already own)


Select metals/mining stocks trading higher: CLF +17.1%, VALE +9.1%, HMY +4.8%, AU +4.6%, MT +2.9%, GFI +2.2%,ABX +1.8%, GDX +1.8%, SLV +1%, BHP +0.8%, GLD +0.6%, AA +0.5%

Select oil/gas related names showing strength: WRES +33.9%, BBEP +25.5%, CHK +7.5%, MRO +3.2%, KMI +2.1%,WLL +1.6%

Other news: BCRX +13.2% (to present results from pre-clinical study of BCX4430 on mice infected with Zika Virus), ICON+12.6% (enters five-year $300 mln senior secured term loan credit facility), CRC +10.8% (cont strength), SUNE +8.4% (cont vol pre-mkt), TRXC +6.2% (cont strength), DBVT +5.9% (presents results from the OLFUS-VIPES trial ), PPHM +5.8% (formally commissions its new commercial biomanufacturing suite in Tustin, California), DSCI +4.6% (announces peer-reviewed clinical study of AmnioExcel has been published in WOUNDS), VRX +4.1% (to host a conference call and live webcast on March 15 to discuss preliminary Q4 financial results and update 2016 financial guidance), MOMO +3.7% (still checking),RESI +3.1% (issues open letter to stockholders in response to RESI Shareholders Group), AGEN +2.9% (files ~1.631 mln share common stock offering by selling stockholders), NCR +1% (announces $250 million share repurchase and increases 2016 full year EPS guidance)